These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 19208462

  • 21. Identification of a key element for hydrogen-bonding patterns between protein kinases and their inhibitors.
    Katayama N, Orita M, Yamaguchi T, Hisamichi H, Kuromitsu S, Kurihara H, Sakashita H, Matsumoto Y, Fujita S, Niimi T.
    Proteins; 2008 Dec; 73(4):795-801. PubMed ID: 18767165
    [Abstract] [Full Text] [Related]

  • 22. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
    Charrier JD, Miller A, Kay DP, Brenchley G, Twin HC, Collier PN, Ramaya S, Keily SB, Durrant SJ, Knegtel RM, Tanner AJ, Brown K, Curnock AP, Jimenez JM.
    J Med Chem; 2011 Apr 14; 54(7):2341-50. PubMed ID: 21391610
    [Abstract] [Full Text] [Related]

  • 23. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.
    Blencke S, Zech B, Engkvist O, Greff Z, Orfi L, Horváth Z, Kéri G, Ullrich A, Daub H.
    Chem Biol; 2004 May 14; 11(5):691-701. PubMed ID: 15157880
    [Abstract] [Full Text] [Related]

  • 24. Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors.
    Marzaro G, Chilin A, Guiotto A, Uriarte E, Brun P, Castagliuolo I, Tonus F, González-Díaz H.
    Eur J Med Chem; 2011 Jun 14; 46(6):2185-92. PubMed ID: 21447431
    [Abstract] [Full Text] [Related]

  • 25. Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors.
    El-Deeb IM, Park BS, Jung SJ, Yoo KH, Oh CH, Cho SJ, Han DK, Lee JY, Lee SH.
    Bioorg Med Chem Lett; 2009 Oct 01; 19(19):5622-6. PubMed ID: 19700314
    [Abstract] [Full Text] [Related]

  • 26. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
    Zhao H, Huang D, Caflisch A.
    ChemMedChem; 2012 Nov 01; 7(11):1983-90. PubMed ID: 22976951
    [Abstract] [Full Text] [Related]

  • 27. Insights for the development of specific kinase inhibitors by targeted structural genomics.
    Fedorov O, Sundström M, Marsden B, Knapp S.
    Drug Discov Today; 2007 May 01; 12(9-10):365-72. PubMed ID: 17467572
    [Abstract] [Full Text] [Related]

  • 28. Imprint of evolutionary conservation and protein structure variation on the binding function of protein tyrosine kinases.
    Verkhivker GM.
    Bioinformatics; 2006 Aug 01; 22(15):1846-54. PubMed ID: 16720585
    [Abstract] [Full Text] [Related]

  • 29. Can MM-PBSA calculations predict the specificities of protein kinase inhibitors?
    Page CS, Bates PA.
    J Comput Chem; 2006 Dec 01; 27(16):1990-2007. PubMed ID: 17036304
    [Abstract] [Full Text] [Related]

  • 30. Structural interaction fingerprints: a new approach to organizing, mining, analyzing, and designing protein-small molecule complexes.
    Singh J, Deng Z, Narale G, Chuaqui C.
    Chem Biol Drug Des; 2006 Jan 01; 67(1):5-12. PubMed ID: 16492144
    [Abstract] [Full Text] [Related]

  • 31. Structural basis for the inhibitor recognition of human Lyn kinase domain.
    Miyano N, Kinoshita T, Nakai R, Kirii Y, Yokota K, Tada T.
    Bioorg Med Chem Lett; 2009 Dec 01; 19(23):6557-60. PubMed ID: 19857964
    [Abstract] [Full Text] [Related]

  • 32. Protein tyrosine kinase-substrate interactions.
    Bose R, Holbert MA, Pickin KA, Cole PA.
    Curr Opin Struct Biol; 2006 Dec 01; 16(6):668-75. PubMed ID: 17085043
    [Abstract] [Full Text] [Related]

  • 33. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.
    Williams NK, Bamert RS, Patel O, Wang C, Walden PM, Wilks AF, Fantino E, Rossjohn J, Lucet IS.
    J Mol Biol; 2009 Mar 20; 387(1):219-32. PubMed ID: 19361440
    [Abstract] [Full Text] [Related]

  • 34. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery.
    Ghose AK, Herbertz T, Pippin DA, Salvino JM, Mallamo JP.
    J Med Chem; 2008 Sep 11; 51(17):5149-71. PubMed ID: 18710211
    [No Abstract] [Full Text] [Related]

  • 35. Engineering the catalytic domain of human protein tyrosine phosphatase beta for structure-based drug discovery.
    Evdokimov AG, Pokross M, Walter R, Mekel M, Cox B, Li C, Bechard R, Genbauffe F, Andrews R, Diven C, Howard B, Rastogi V, Gray J, Maier M, Peters KG.
    Acta Crystallogr D Biol Crystallogr; 2006 Dec 11; 62(Pt 12):1435-45. PubMed ID: 17139078
    [Abstract] [Full Text] [Related]

  • 36. Targeting cancer with small-molecular-weight kinase inhibitors.
    Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G.
    Methods Mol Biol; 2012 Dec 11; 795():1-34. PubMed ID: 21960212
    [Abstract] [Full Text] [Related]

  • 37. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
    Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C.
    J Med Chem; 2009 Oct 22; 52(20):6433-46. PubMed ID: 19788238
    [Abstract] [Full Text] [Related]

  • 38. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.
    Bamborough P, Drewry D, Harper G, Smith GK, Schneider K.
    J Med Chem; 2008 Dec 25; 51(24):7898-914. PubMed ID: 19035792
    [Abstract] [Full Text] [Related]

  • 39. Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.
    Getlik M, Grütter C, Simard JR, Klüter S, Rabiller M, Rode HB, Robubi A, Rauh D.
    J Med Chem; 2009 Jul 09; 52(13):3915-26. PubMed ID: 19462975
    [Abstract] [Full Text] [Related]

  • 40. New protein kinase CK2 inhibitors: jumping out of the catalytic box.
    Prudent R, Cochet C.
    Chem Biol; 2009 Feb 27; 16(2):112-20. PubMed ID: 19246001
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.